Literature DB >> 32447425

Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease.

Luca Roncati1, Beatrice Lusenti2, Vincenzo Nasillo2, Antonio Manenti3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32447425      PMCID: PMC7245576          DOI: 10.1007/s00277-020-04098-z

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
Dear Editor, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the ongoing pandemic named coronavirus disease 2019 (COVID-19), and new knowledge about this novel virus is needed also through anecdotal cases. A 70-year-old Italian male patient with hepatosplenomegaly and moderate anemia was submitted to full-body computed tomography (CT) scan with contrast medium, which showed multiple supra-/subdiaphragmatic lymphadenopathies and a right axillary adenomegaly (Fig. 1a); therefore, axillary node and then bone marrow core biopsies were performed. Both the specimens revealed an Epstein-Barr virus (EBV)–associated lymphoproliferative disease (Fig. 1b), with the characteristics of classical Hodgkin lymphoma. Meanwhile, the patient manifested hyperpyrexia accompanied by dyspnea and a nasopharyngeal swab was found positive for SARS-CoV-2. The chest X-ray obtained at the patient’s bed in isolation hospital room highlighted a bilateral interstitial pneumonia (Fig. 1c), and the patient died after 13 days from the admission for its complications despite therapy. To date, in about the 10–15% of affected patients, especially the elderly and those with pre-existing health issues or immunocompromised, COVID-19 can progress from mild symptoms or signs, such as low-grade fever, headache, conjunctivitis, rhinorrhea, anosmia, pharyngodynia, ageusia, cough, chills, myalgia, asthenia, skin rash, nausea vomiting, and diarrhea, to pneumonia, acute respiratory distress syndrome, renal insufficiency, disseminate intravascular coagulation, and multiple organ failure [1]. A marked lymphopenia has been observed in the most serious cases of the disease [2]. EBV belongs to the Herpesviridae family and causes infectious mononucleosis as well as chronic active infections; besides, it can induce various pre-cancerous or cancerous lymphoproliferative disorders, such as mucocutaneous ulcer, Hodgkin lymphoma, Burkitt lymphoma, diffuse large B cell lymphoma, plasmablastic lymphoma, plasma cell myeloma, angioimmunoblastic T cell lymphoma, follicular T cell lymphoma, extranodal NK/T cell lymphoma, and aggressive NK cell leukemia, particularly in immunodeficient and/or post-transplanted patients [3]. In these subjects, the synergic action of EBV and SARS-CoV-2 is assumed to be burden by a very high fatality rate.
Fig. 1

An axial plan of the CT scan with contrast medium shows a 6.5 × 5.0 cm mass (a, yellow dashed circle) in the right axillary cable. The in situ hybridization for EBV (EBER probe, × 10 objective) points out several positive blue-stained Hodgkin cells inside the core needle biopsy, taken from the axillary mass (b, on the left), and in the bone marrow specimen (b, on the right). The chest X-ray performed at the patient’s bed in isolation hospital room shows a diffuse bilateral interstitial pneumonia (c)

An axial plan of the CT scan with contrast medium shows a 6.5 × 5.0 cm mass (a, yellow dashed circle) in the right axillary cable. The in situ hybridization for EBV (EBER probe, × 10 objective) points out several positive blue-stained Hodgkin cells inside the core needle biopsy, taken from the axillary mass (b, on the left), and in the bone marrow specimen (b, on the right). The chest X-ray performed at the patient’s bed in isolation hospital room shows a diffuse bilateral interstitial pneumonia (c)
  3 in total

Review 1.  Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification.

Authors:  Hyun-Jung Kim; Young Hyeh Ko; Ji Eun Kim; Seung-Sook Lee; Hyekyung Lee; Gyeongsin Park; Jin Ho Paik; Hee Jeong Cha; Yoo-Duk Choi; Jae Ho Han; Jooryung Huh
Journal:  J Pathol Transl Med       Date:  2017-06-05

2.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.

Authors:  Li Tan; Qi Wang; Duanyang Zhang; Jinya Ding; Qianchuan Huang; Yi-Quan Tang; Qiongshu Wang; Hongming Miao
Journal:  Signal Transduct Target Ther       Date:  2020-03-27

3.  Clinical characteristics of 3062 COVID-19 patients: A meta-analysis.

Authors:  Jieyun Zhu; Pan Ji; Jielong Pang; Zhimei Zhong; Hongyuan Li; Cuiying He; Jianfeng Zhang; Chunling Zhao
Journal:  J Med Virol       Date:  2020-06-24       Impact factor: 20.693

  3 in total
  4 in total

1.  Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients.

Authors:  Ting Chen; Jiayi Song; Hongli Liu; Hongmei Zheng; Changzheng Chen
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 2.  Viral coinfections in COVID-19.

Authors:  Parisa S Aghbash; Narges Eslami; Milad Shirvaliloo; Hossein B Baghi
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

3.  Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study.

Authors:  Irene Soffritti; Maria D'Accolti; Chiara Fabbri; Angela Passaro; Roberto Manfredini; Giovanni Zuliani; Marco Libanore; Maurizio Franchi; Carlo Contini; Elisabetta Caselli
Journal:  Front Microbiol       Date:  2021-06-23       Impact factor: 5.640

4.  Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.

Authors:  Debmalya Barh; Sandeep Tiwari; Lucas Gabriel Rodrigues Gomes; Marianna E Weener; Khalid J Alzahrani; Khalaf F Alsharif; Alaa A A Aljabali; Murtaza M Tambuwala; Kenneth Lundstrom; Sk Sarif Hassan; Ángel Serrano-Aroca; Kazuo Takayama; Preetam Ghosh; Elrashdy M Redwan; Bruno Silva Andrade; Siomar de Castro Soares; Vasco Azevedo; Vladimir N Uversky
Journal:  Viruses       Date:  2021-09-25       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.